(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutaneum hydrochloridum CAS 866783-13-3 Puritas >99.5%
Ruifu Chemical Supple Ivabradine Hydrochloride media Cum High puritate
Ivabradine Hydrochloride CAS 148849-67-6
4,5-Dimethoxy-1-Cyanobenzocyclobutaneum CAS 35202-54-1
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutaneum hydrochloridum CAS 866783-13-3
7,8-Dimethoxy-1,3-dihydro-2H-3-benzazepin-2-one CAS 73942-87-7
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one CAS 148870-57-9
3-(3-Chloropropyl)-7,8-dimethoxy-1H-3-benzazepin-2(3H)-one CAS 85175-59-3
Nomen chemicum | (1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutaneum hydrochloridum |
Synonyma | Ivabradine Hydrochloride Intermedia;(1S)-4,5-Dimethoxy-1-(Methylaminomethyl)-Benzocyclobutane HCl |
CAS Number | 866783-13-3 |
CATTUS Number | RF-PI1811 |
Stock Status | In Stock, Productio Ascendite ad Tons |
Formulae hypotheticae | C12H18ClNO2 |
M. Pondus | 243.73 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Alba ad Off-White pulveris |
Lepidium sativum | HPLC/UV obsequium |
Imprimis Rotationes | +14.0° ~ +19.0° (1% CH3OH) |
Damnum in Siccatio | <0.50% (sicco in 105℃ in vacuo usque ad pondus constans) |
Individual Impurity | <0.50% |
Optical Isomers | <0.50% |
Puritas / Analysis Methodus | >99.5% (% area ordinationem, per HPLC) |
Assay | 99.0%~ 100.5% (in fundamento exsiccato, per Titration) |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia Ivabradine Hydrochloridis (CAS: 148849-67-6) |
sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore
(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutaneum hydrochloridum (CAS: 866783-13-3) medium adhibitum est in praeparatione Hydrochloridis Ivabradini (CAS: 148849-67-6) quod est. selectivum procuratorem bradycardinum cum effectu directo in pacemaker Si currens nodi sinoatrialis.Ivabradine celeritatem diastolicae depolarizationis minuit et rate cor minuit.Probatum est ad anginas firmas chronicas curandas et viabile optionem praebet aegris contraindicationem vel intolerantia obstructorum b.Aestimatio etiam comparata potentiali curationis ischemicae morbi cordis est.